APO Research
Talk to an analyst

APO RESEARCH · REPORT

Aminoglycosides Antibiotics Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Aminoglycosides Antibiotics Drug Market Outlook and Growth Opportunities 2026

2 January 2026191 pages

Choose your research edition.

Industry ResearchAminoglycosides Antibiotics Drug Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Aminoglycosides Antibiotics Drug Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Aminoglycosides Antibiotics Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Aminoglycosides Antibiotics Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Aminoglycosides Antibiotics Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Aminoglycosides Antibiotics Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Aminoglycosides Antibiotics Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Aminoglycosides Antibiotics Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Aminoglycosides Antibiotics Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Aminoglycosides Antibiotics Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Aminoglycosides Antibiotics Drug market include Teva, Novartis, Pfizer, Fresenius Kabi, Sun Pharma, Lannett Company, Jemicare, Hikma and Fangyuan-pharma, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Aminoglycosides Antibiotics Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Aminoglycosides Antibiotics Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Aminoglycosides Antibiotics Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Aminoglycosides Antibiotics Drug market.

Aminoglycosides Antibiotics Drug Segment by Company

Teva

Novartis

Pfizer

Fresenius Kabi

Sun Pharma

Lannett Company

Jemicare

Hikma

Fangyuan-pharma

Cipla

Aike Pharmaceutical

Aminoglycosides Antibiotics Drug Segment by Type

Etimicin

Neomycin

Tobramycin

Gentamicin

Amikacin

Others

Aminoglycosides Antibiotics Drug Segment by Application

Hospital

Clinic

Others

Aminoglycosides Antibiotics Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Aminoglycosides Antibiotics Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Aminoglycosides Antibiotics Drug key companies, revenue, market share, and recent developments.

3. To split the Aminoglycosides Antibiotics Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Aminoglycosides Antibiotics Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Aminoglycosides Antibiotics Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Aminoglycosides Antibiotics Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Aminoglycosides Antibiotics Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Aminoglycosides Antibiotics Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Aminoglycosides Antibiotics Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Aminoglycosides Antibiotics Drug industry.

Chapter 3: Detailed analysis of Aminoglycosides Antibiotics Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Aminoglycosides Antibiotics Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Aminoglycosides Antibiotics Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Aminoglycosides Antibiotics Drug Industry Trends Table 2. Aminoglycosides Antibiotics Drug Industry Drivers Table 3. Aminoglycosides Antibiotics Drug Industry Opportunities and Challenges Table 4. Aminoglycosides Antibiotics Drug Industry Restraints Table 5. Global Aminoglycosides Antibiotics Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Aminoglycosides Antibiotics Drug Revenue Share by Company (2021-2026) Table 7. Global Aminoglycosides Antibiotics Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Aminoglycosides Antibiotics Drug Key Company Manufacturing Base & Headquarters Table 9. Global Aminoglycosides Antibiotics Drug Company, Product Type & Application Table 10. Global Aminoglycosides Antibiotics Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Aminoglycosides Antibiotics Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Etimicin Table 15. Significant Companies of Neomycin Table 16. Significant Companies of Tobramycin Table 17. Significant Companies of Gentamicin Table 18. Significant Companies of Amikacin Table 19. Significant Companies of Others Table 20. Global Aminoglycosides Antibiotics Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Aminoglycosides Antibiotics Drug Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Aminoglycosides Antibiotics Drug Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Aminoglycosides Antibiotics Drug Sales Value Share by Type (2021-2026) Table 24. Global Aminoglycosides Antibiotics Drug Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Hospital Table 26. Significant Companies of Clinic Table 27. Significant Companies of Others Table 28. Global Aminoglycosides Antibiotics Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Aminoglycosides Antibiotics Drug Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Aminoglycosides Antibiotics Drug Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Aminoglycosides Antibiotics Drug Sales Value Share by Application (2021-2026) Table 32. Global Aminoglycosides Antibiotics Drug Sales Value Share by Application (2027-2032) Table 33. Global Aminoglycosides Antibiotics Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Aminoglycosides Antibiotics Drug Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Aminoglycosides Antibiotics Drug Sales Value Share by Region (2021-2026) Table 36. Global Aminoglycosides Antibiotics Drug Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Aminoglycosides Antibiotics Drug Sales Value Share by Region (2027-2032) Table 38. Global Aminoglycosides Antibiotics Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Aminoglycosides Antibiotics Drug Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Aminoglycosides Antibiotics Drug Sales Value Market Share by Country (2021-2026) Table 41. Global Aminoglycosides Antibiotics Drug Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Aminoglycosides Antibiotics Drug Sales Value Market Share by Country (2027-2032) Table 43. Teva Company Information Table 44. Teva Business Overview Table 45. Teva Aminoglycosides Antibiotics Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Teva Aminoglycosides Antibiotics Drug Product Portfolio Table 47. Teva Recent Development Table 48. Novartis Company Information Table 49. Novartis Business Overview Table 50. Novartis Aminoglycosides Antibiotics Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Novartis Aminoglycosides Antibiotics Drug Product Portfolio Table 52. Novartis Recent Development Table 53. Pfizer Company Information Table 54. Pfizer Business Overview Table 55. Pfizer Aminoglycosides Antibiotics Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Pfizer Aminoglycosides Antibiotics Drug Product Portfolio Table 57. Pfizer Recent Development Table 58. Fresenius Kabi Company Information Table 59. Fresenius Kabi Business Overview Table 60. Fresenius Kabi Aminoglycosides Antibiotics Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Fresenius Kabi Aminoglycosides Antibiotics Drug Product Portfolio Table 62. Fresenius Kabi Recent Development Table 63. Sun Pharma Company Information Table 64. Sun Pharma Business Overview Table 65. Sun Pharma Aminoglycosides Antibiotics Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Sun Pharma Aminoglycosides Antibiotics Drug Product Portfolio Table 67. Sun Pharma Recent Development Table 68. Lannett Company Company Information Table 69. Lannett Company Business Overview Table 70. Lannett Company Aminoglycosides Antibiotics Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Lannett Company Aminoglycosides Antibiotics Drug Product Portfolio Table 72. Lannett Company Recent Development Table 73. Jemicare Company Information Table 74. Jemicare Business Overview Table 75. Jemicare Aminoglycosides Antibiotics Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Jemicare Aminoglycosides Antibiotics Drug Product Portfolio Table 77. Jemicare Recent Development Table 78. Hikma Company Information Table 79. Hikma Business Overview Table 80. Hikma Aminoglycosides Antibiotics Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Hikma Aminoglycosides Antibiotics Drug Product Portfolio Table 82. Hikma Recent Development Table 83. Fangyuan-pharma Company Information Table 84. Fangyuan-pharma Business Overview Table 85. Fangyuan-pharma Aminoglycosides Antibiotics Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Fangyuan-pharma Aminoglycosides Antibiotics Drug Product Portfolio Table 87. Fangyuan-pharma Recent Development Table 88. Cipla Company Information Table 89. Cipla Business Overview Table 90. Cipla Aminoglycosides Antibiotics Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Cipla Aminoglycosides Antibiotics Drug Product Portfolio Table 92. Cipla Recent Development Table 93. Aike Pharmaceutical Company Information Table 94. Aike Pharmaceutical Business Overview Table 95. Aike Pharmaceutical Aminoglycosides Antibiotics Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Aike Pharmaceutical Aminoglycosides Antibiotics Drug Product Portfolio Table 97. Aike Pharmaceutical Recent Development Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. Aminoglycosides Antibiotics Drug Product Image Figure 2. Global Aminoglycosides Antibiotics Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Aminoglycosides Antibiotics Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Aminoglycosides Antibiotics Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Etimicin Image Figure 8. Neomycin Image Figure 9. Tobramycin Image Figure 10. Gentamicin Image Figure 11. Amikacin Image Figure 12. Others Image Figure 13. Global Aminoglycosides Antibiotics Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Aminoglycosides Antibiotics Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Aminoglycosides Antibiotics Drug Sales Value Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Others Image Figure 19. Global Aminoglycosides Antibiotics Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Aminoglycosides Antibiotics Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Aminoglycosides Antibiotics Drug Sales Value Share by Application (2021-2032) Figure 22. Global Aminoglycosides Antibiotics Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Aminoglycosides Antibiotics Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Aminoglycosides Antibiotics Drug Sales Value (2021-2032) & (US$ Million) Figure 25. North America Aminoglycosides Antibiotics Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Aminoglycosides Antibiotics Drug Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Aminoglycosides Antibiotics Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Aminoglycosides Antibiotics Drug Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Aminoglycosides Antibiotics Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Aminoglycosides Antibiotics Drug Sales Value (2021-2032) & (US$ Million) Figure 31. South America Aminoglycosides Antibiotics Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Aminoglycosides Antibiotics Drug Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Aminoglycosides Antibiotics Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Etimicin
  • Neomycin
  • Tobramycin
  • Gentamicin
  • Amikacin
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Teva
  • Novartis
  • Pfizer
  • Fresenius Kabi
  • Sun Pharma
  • Lannett Company
  • Jemicare
  • Hikma
  • Fangyuan-pharma
  • Cipla
  • Aike Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Aminoglycosides Antibiotics Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Aminoglycosides Antibiotics Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Aminoglycosides Antibiotics Drug Market Dynamics
  1. 2.1 Aminoglycosides Antibiotics Drug Industry Trends
  2. 2.2 Aminoglycosides Antibiotics Drug Industry Drivers
  3. 2.3 Aminoglycosides Antibiotics Drug Industry Opportunities and Challenges
  4. 2.4 Aminoglycosides Antibiotics Drug Industry Restraints
3 Aminoglycosides Antibiotics Drug Market by Company
  1. 3.1 Global Aminoglycosides Antibiotics Drug Company Revenue Ranking in 2025
  2. 3.2 Global Aminoglycosides Antibiotics Drug Revenue by Company (2021-2026)
  3. 3.3 Global Aminoglycosides Antibiotics Drug Company Ranking (2024-2026)
  4. 3.4 Global Aminoglycosides Antibiotics Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Aminoglycosides Antibiotics Drug Company Product Type and Application
  6. 3.6 Global Aminoglycosides Antibiotics Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Aminoglycosides Antibiotics Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Aminoglycosides Antibiotics Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Aminoglycosides Antibiotics Drug Market by Type
  1. 4.1 Aminoglycosides Antibiotics Drug Type Introduction
  2. 4.1.1 Etimicin
  3. 4.1.2 Neomycin
  4. 4.1.3 Tobramycin
  5. 4.1.4 Gentamicin
  6. 4.1.5 Amikacin
  7. 4.1.6 Others
  8. 4.2 Global Aminoglycosides Antibiotics Drug Sales Value by Type
  9. 4.2.1 Global Aminoglycosides Antibiotics Drug Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Aminoglycosides Antibiotics Drug Sales Value by Type (2021-2032)
  11. 4.2.3 Global Aminoglycosides Antibiotics Drug Sales Value Share by Type (2021-2032)
5 Aminoglycosides Antibiotics Drug Market by Application
  1. 5.1 Aminoglycosides Antibiotics Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Aminoglycosides Antibiotics Drug Sales Value by Application
  6. 5.2.1 Global Aminoglycosides Antibiotics Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Aminoglycosides Antibiotics Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Aminoglycosides Antibiotics Drug Sales Value Share by Application (2021-2032)
6 Aminoglycosides Antibiotics Drug Regional Value Analysis
  1. 6.1 Global Aminoglycosides Antibiotics Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Aminoglycosides Antibiotics Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Aminoglycosides Antibiotics Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Aminoglycosides Antibiotics Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Aminoglycosides Antibiotics Drug Sales Value (2021-2032)
  7. 6.3.2 North America Aminoglycosides Antibiotics Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Aminoglycosides Antibiotics Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Aminoglycosides Antibiotics Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Aminoglycosides Antibiotics Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Aminoglycosides Antibiotics Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Aminoglycosides Antibiotics Drug Sales Value (2021-2032)
  16. 6.6.2 South America Aminoglycosides Antibiotics Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Aminoglycosides Antibiotics Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Aminoglycosides Antibiotics Drug Sales Value Share by Country, 2025 VS 2032
7 Aminoglycosides Antibiotics Drug Country-level Value Analysis
  1. 7.1 Global Aminoglycosides Antibiotics Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Aminoglycosides Antibiotics Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Aminoglycosides Antibiotics Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Aminoglycosides Antibiotics Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Aminoglycosides Antibiotics Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Aminoglycosides Antibiotics Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Aminoglycosides Antibiotics Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Aminoglycosides Antibiotics Drug Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Aminoglycosides Antibiotics Drug Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Aminoglycosides Antibiotics Drug Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Fresenius Kabi
  20. 8.4.1 Fresenius Kabi Company Information
  21. 8.4.2 Fresenius Kabi Business Overview
  22. 8.4.3 Fresenius Kabi Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Fresenius Kabi Aminoglycosides Antibiotics Drug Product Portfolio
  24. 8.4.5 Fresenius Kabi Recent Developments
  25. 8.5 Sun Pharma
  26. 8.5.1 Sun Pharma Company Information
  27. 8.5.2 Sun Pharma Business Overview
  28. 8.5.3 Sun Pharma Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sun Pharma Aminoglycosides Antibiotics Drug Product Portfolio
  30. 8.5.5 Sun Pharma Recent Developments
  31. 8.6 Lannett Company
  32. 8.6.1 Lannett Company Company Information
  33. 8.6.2 Lannett Company Business Overview
  34. 8.6.3 Lannett Company Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Lannett Company Aminoglycosides Antibiotics Drug Product Portfolio
  36. 8.6.5 Lannett Company Recent Developments
  37. 8.7 Jemicare
  38. 8.7.1 Jemicare Company Information
  39. 8.7.2 Jemicare Business Overview
  40. 8.7.3 Jemicare Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Jemicare Aminoglycosides Antibiotics Drug Product Portfolio
  42. 8.7.5 Jemicare Recent Developments
  43. 8.8 Hikma
  44. 8.8.1 Hikma Company Information
  45. 8.8.2 Hikma Business Overview
  46. 8.8.3 Hikma Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hikma Aminoglycosides Antibiotics Drug Product Portfolio
  48. 8.8.5 Hikma Recent Developments
  49. 8.9 Fangyuan-pharma
  50. 8.9.1 Fangyuan-pharma Company Information
  51. 8.9.2 Fangyuan-pharma Business Overview
  52. 8.9.3 Fangyuan-pharma Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Fangyuan-pharma Aminoglycosides Antibiotics Drug Product Portfolio
  54. 8.9.5 Fangyuan-pharma Recent Developments
  55. 8.10 Cipla
  56. 8.10.1 Cipla Company Information
  57. 8.10.2 Cipla Business Overview
  58. 8.10.3 Cipla Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Cipla Aminoglycosides Antibiotics Drug Product Portfolio
  60. 8.10.5 Cipla Recent Developments
  61. 8.11 Aike Pharmaceutical
  62. 8.11.1 Aike Pharmaceutical Company Information
  63. 8.11.2 Aike Pharmaceutical Business Overview
  64. 8.11.3 Aike Pharmaceutical Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Aike Pharmaceutical Aminoglycosides Antibiotics Drug Product Portfolio
  66. 8.11.5 Aike Pharmaceutical Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst